Najafi Zahra, Zandi Haramabadi Maryam, Chehardoli Gholamabbas, Ebadi Ahmad, Iraji Aida
Department of Medicinal Chemistry, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, Iran.
Department of Medicinal Chemistry, School of Pharmacy, Medicinal Plants and Natural Products Research Center, Hamadan University of Medical Sciences, Hamadan, Iran.
BMC Chem. 2024 Feb 22;18(1):41. doi: 10.1186/s13065-024-01134-1.
A novel series of kojic acid fused 2-amino-3-cyano-4H-pyran derivatives were synthesized via a multicomponent reaction involving kojic acid, benzyloxy benzaldehyde, and malonitrile as tyrosinase inhibitors. Subsequently, the structures of the compounds were characterized using FT-IR, H-, and C-NMR spectroscopic analyses. The designed compounds fall into three series: (1) 4-benzyloxy-phenyl kojopyran 6a-e, (2) 3-benzyloxy- phenyl kojopyran derivatives 6f-j, and (3) 4-benzyloxy-3-methoxy-phenyl kojopyran derivative 6 k-o. The assessment of tyrosinase inhibition activity was conducted using L-Dopa as the substrate. Among synthesized compounds, 2-amino-4-(4-((4-fluorobenzyl)oxy)phenyl)-6-(hydroxymethyl)-8-oxo-4,8-dihydropyrano[3,2-b]pyran-3-carbonitrile (6b) demonstrated the highest antityrosinase activity with a competitive inhibition pattern (IC = 7.69 ± 1.99 μM) as compared to the control agent kojic acid (IC = 23.64 ± 2.56 µM). Since compound 6b was synthesized as a racemic mixture, in silico studies were performed for both R and S enantiomers. The R- enantiomer showed critical interactions compared with the S-enantiomer. Specifically, it established hydrogen bonds and hydrophobic interactions with crucial and highly conserved amino acids within the enzyme's binding site in the target protein. Moreover, the molecular dynamics simulations revealed that compound 6b demonstrated significant interactions with essential residues of the binding site, resulting in a stable complex throughout the entire simulation run. The drug-like and ADMET properties predictions showed an acceptable profile for compound 6b. Thus, it can serve as a drug candidate to develop more potent antityrosinase agents due to its low toxicity and its high inhibition activity.
通过涉及曲酸、苄氧基苯甲醛和丙二腈的多组分反应合成了一系列新型的曲酸稠合2-氨基-3-氰基-4H-吡喃衍生物作为酪氨酸酶抑制剂。随后,使用傅里叶变换红外光谱(FT-IR)、氢核磁共振(H-NMR)和碳核磁共振(C-NMR)光谱分析对化合物的结构进行了表征。设计的化合物分为三个系列:(1)4-苄氧基苯基曲酸吡喃6a-e,(2)3-苄氧基苯基曲酸吡喃衍生物6f-j,以及(3)4-苄氧基-3-甲氧基苯基曲酸吡喃衍生物6k-o。以L-多巴为底物进行酪氨酸酶抑制活性评估。在合成的化合物中,2-氨基-4-(4-((4-氟苄基)氧基)苯基)-6-(羟甲基)-8-氧代-4,8-二氢吡喃并[3,2-b]吡喃-3-腈(6b)表现出最高的抗酪氨酸酶活性,与对照剂曲酸(IC = 23.64 ± 2.56 μM)相比具有竞争性抑制模式(IC = 7.69 ± 1.99 μM)。由于化合物6b是作为外消旋混合物合成的,因此对R和S对映体都进行了计算机模拟研究。与S-对映体相比,R-对映体显示出关键的相互作用。具体而言,它与目标蛋白中酶结合位点内的关键且高度保守的氨基酸建立了氢键和疏水相互作用。此外,分子动力学模拟表明化合物6b与结合位点的必需残基表现出显著的相互作用,在整个模拟过程中形成了稳定的复合物。药物类性质和ADMET性质预测显示化合物6b具有可接受的特性。因此,由于其低毒性和高抑制活性,它可以作为开发更有效抗酪氨酸酶药物的候选药物。